Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Patriot Act signed

This article was originally published in The Tan Sheet

Executive Summary

The U.S. Patriot Improvement & Reauthorization Act, which contains meth control provisions that will go into effect in mid April, was signed by President Bush March 9. Elements of the Combat Meth Act included in the bill require behind-the-counter sale of pseudoephedrine products by Sept. 30, and a sales limit of 3.6 g/day and 9 g/month of OTCs containing pseudoephedrine, ephedrine or phenylpropanolamine. The bill passed the Senate March 2 (1"The Tan Sheet" March 6, 2006, p. 5)...

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts